BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Prompted by this observation, landmark survival analyses were performed for 1342 evaluable patients in the German CML IV study, who achieved BCR::ABL1IS < 0.1%, 0.1%–1%, >1%–10% or >10% at 3, 6, 12, and 24 months.